The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Melanoma is the 4th most common cancer diagnosed in Australia. Advanced melanoma frequently spreads to other organs and can acquire resistance to anti-melanoma treatments, making it fundamentally incurable. I am focused on investigating the mechanisms underlying melanoma disease progression. I will achieve this by comparing the biological nature of melanoma cells at different stages of disease and therapy-resistance to identify new targets for the more effective treatment of patients with melano ....Melanoma is the 4th most common cancer diagnosed in Australia. Advanced melanoma frequently spreads to other organs and can acquire resistance to anti-melanoma treatments, making it fundamentally incurable. I am focused on investigating the mechanisms underlying melanoma disease progression. I will achieve this by comparing the biological nature of melanoma cells at different stages of disease and therapy-resistance to identify new targets for the more effective treatment of patients with melanoma.Read moreRead less
Deep Brain Stimulation For Treatment Resistant Major Depression: Neural Correlates And Neuropsychological Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$257,561.00
Summary
Major depression is a prevalent and devastating mental illness. While there are numerous pharmacological and psychological antidepressant therapies available, many patients do not respond to these treatments. Deep Brain Stimulation (DBS) is emerging as a potential treatment option for individuals with chronic severe treatment resistant major depression. The current project will investigate the cognitive and neurobiological outcomes associated with the use of DBS to treat depression.
Targeting Survival Pathways To Overcome The Resistance Of Human Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$332,123.00
Summary
Melanoma is a major Australian health problem. This is believed to be due to resistance of melanoma cells to cell death associated with inappropriate activation of survival signalling pathways. My previous studies have provided a number of insights into resistance mechanisms of melanoma cells to apoptosis. I wish to understand more fully the molecular basis of the survival signalling pathways, and to identify new therapeutic targets for overcoming resistance of melanoma to treatment.
Combined Therapy To Ameliorate Ventilatory Instability In Patients With Heart Failure And Sleep Apnea
Funder
National Health and Medical Research Council
Funding Amount
$386,648.00
Summary
Sleep apnea is highly prevalent, particularly in patients with heart failure, and treatment remains limited to applying pressure via a face mask which can be intolerable. Although instability in breathing control is a major cause of apnea in many patients, treatments targeting instability with sufficient efficacy are unavailable. This project will combine two treatments, acetazolamide and oxygen, to powerfully reduce instability and provide relief from sleep apnea in a subgroup of patients.
A Biomimetic Prodrug Platform To Enable Oral Bioavailability And Target Lymphatic Disease
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
This project will allow the advance of a unique translational technology platform that provides novel drug delivery solutions. The project aims to establish the potential for a drug delivery strategy to increase the efficacy, reduce the toxicity, and transform the impact of drug therapies for a variety of conditions, including pain, hormone dysregulation, and metabolic syndrome.
New drugs for cancer therapy that overcome resistance to standard chemotherapeutics and stop the spread of cancer are essential to develop. My preliminary studies discovered a strategy to increase the activity and delivery of our novel compounds to enhance the killing of cancer cells. I will design innovative agents in an effort to provide more effective therapeutics with fewer side effects to reduce the pain of cancer patients undertaking chemotherapy who are in the battle of their lives.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.